<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-263 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-263</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-263</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-12.html">extraction-schema-12</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <p><strong>Paper ID:</strong> paper-a53be620e7ea9fb086c35cfedce855aaf73252b1</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/a53be620e7ea9fb086c35cfedce855aaf73252b1" target="_blank">Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database</a></p>
                <p><strong>Paper Venue:</strong> Journal of Thoracic Oncology</p>
                <p><strong>Paper TL;DR:</strong> Using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features but were not an independent prognostic factor for patients with TET’s.</p>
                <p><strong>Cost:</strong> 0.018</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e263.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e263.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MG</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Myasthenia gravis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An autoimmune disorder of the neuromuscular junction most commonly mediated by autoantibodies (commonly against the acetylcholine receptor) and the predominant paraneoplastic autoimmune syndrome associated with thymomas.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td>Approximately 30% (literature estimate); 32.8% of the ITMIG cohort (2068/6297 TET patients had MG; PN/AI overall 34.0%)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Autoantibody-mediated disease driven by thymoma-associated defects in thymic selection and antigen presentation leading to escape and peripheral activation of autoreactive T and B cells that produce anti‑AChR and other autoantibodies.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Epidemiologic association in multiple databases; presence of AChR and other autoantibodies in many patients; immunologic studies showing thymomas enriched for AChR-reactive T cells and altered circulating T-cell subsets in thymoma-associated MG (see refs in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Seronegative MG cases occur in association with thymoma, indicating alternative or additional mechanisms beyond classic autoantibody-mediated disease.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td>In ITMIG cohort, MG/PN-AI(+) patients were younger (median 50 vs. 55 years), more often female, and more often European; PN/AI(+) tumors were more often WHO B2 histotype and earlier stage.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>Thymectomy (total/en bloc thymectomy) is associated with attempts at MG remission; an international randomized trial (Wolfe et al., 2016) demonstrated benefit of thymectomy for non-thymomatous MG; in this cohort PN/AI(+) patients underwent total thymectomy more often (90% vs. 77%).</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>MG is the predominant PN/AI syndrome in thymomas; PN/AI(+) patients present at younger age, with favorable tumor features (B2 histotype, earlier stage), higher rates of total thymectomy and R0 resection, and improved unadjusted survival and lower recurrence incidence, but PN/AI status is not an independent prognostic factor in multivariate analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Association data are from retrospective, multi-institutional registry with no central MG serology standardization and variable missingness; lead-time bias and incomplete follow-up may affect prevalence and outcome estimates.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e263.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AIRE deficiency</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Autoimmune regulator (AIRE) deficiency in thymomas</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss or deficiency of the AIRE transcription factor in thymic epithelial cells, which normally promotes promiscuous expression of peripheral self-antigens in the medulla to mediate negative selection and central tolerance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis and other paraneoplastic autoimmune syndromes associated with thymoma</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td>>95% of thymomas lack AIRE expression (as reported in referenced studies)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Absent or reduced AIRE expression in thymoma epithelium reduces promiscuous self-antigen expression in thymic medulla, impairing negative selection of autoreactive T cells and permitting release of self-reactive T-cell clones to the periphery.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Immunohistochemical and molecular studies demonstrating absence of AIRE expression in the vast majority of thymomas; biological role of AIRE in central tolerance is well established in the literature.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Referenced data indicate AIRE deficiency in thymomas alone is insufficient to produce APS-1-like syndrome, implying additional factors are required to produce clinical autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>AIRE is absent in the vast majority (>95%) of thymomas, providing a plausible mechanistic link to defective central tolerance and paraneoplastic autoimmunity, though absence of AIRE by itself may not fully explain the clinical spectrum.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Evidence is correlative (AIRE absence in tumors) and clinical causation is not proven; referenced work shows insufficiency of AIRE loss alone to produce full autoimmune syndromes.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e263.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MHCII reduction</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Decreased major histocompatibility class II (MHC II/HLA-DR) expression on thymic epithelial cells</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Reduced expression of MHC class II molecules on thymoma epithelial cells, which can impair positive and/or negative selection of thymocytes and skew the emerging T-cell repertoire.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis (and related PN/AI syndromes)</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Lower MHC II expression reduces appropriate antigen presentation during thymic selection, causing biased or ineffective selection and survival of autoreactive T-cell clones.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Studies cited show decreased MHC II expression in thymoma epithelial cells; genetic analyses implicating MHC II and AIRE gene roles in thymoma-associated MG.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Decreased MHC II expression in thymoma epithelium, together with reduced self-antigen expression (e.g., AIRE loss), likely contributes to a biased and insufficiently tolerized T-cell repertoire that underlies paraneoplastic autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Mechanistic inference is based on observational molecular/histologic data; functional causation in humans is indirect.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e263.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Intratumoral thymopoiesis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Abnormal intratumoral thymopoiesis and deranged tumor microenvironment</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Thymomas create an abnormal microenvironment that enables aberrant intratumoral maturation/selection of thymocytes, resulting in export of improperly tolerized T cells.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis and other thymoma-associated autoimmune syndromes</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Tumor-associated thymopoiesis produces mature T cells with altered selection (positive/negative) due to abnormal epithelial cell function and antigen presentation, seeding the periphery with autoreactive clones.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Referenced studies report altered peripheral T-cell subset composition in patients with thymoma (supporting abnormal intratumoral thymopoiesis); histologic descriptions of thymomas showing immature thymic architecture and lymphocyte-rich regions.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>The concept of intratumoral thymopoiesis in thymomas provides a plausible mechanism linking thymoma biology to systemic autoimmunity by generating improperly tolerized T cells.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Most evidence is from observational immunophenotyping and histology; direct tracking of tumor-derived autoreactive T cells causing clinical autoimmunity is limited.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e263.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CD4+CD45RA+ expansion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Increased circulating mature CD4+ / CD45RA+ T-cells in thymoma-associated MG</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An immunophenotypic observation that patients with thymoma-associated myasthenia gravis have increased numbers of circulating mature CD4+CD45RA+ T cells compared to thymoma patients without MG.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Expansion/export of mature naive/mature CD4+ T cells from thymoma may reflect altered selection processes, increasing the pool of T cells that can provide help to autoreactive B cells producing pathogenic autoantibodies.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Flow cytometry/immunophenotyping studies cited (Strobel et al.) showing increased circulating mature CD4+/CD45RA+ cells in thymoma-associated MG patients.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Specific peripheral T-cell subset alterations (increased mature CD4+CD45RA+ cells) correlate with paraneoplastic MG, supporting a cellular immunologic basis for autoimmunity in thymoma patients.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Observational association; causal relationship between these cells and autoantibody production or clinical MG not definitively shown.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e263.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Treg loss</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Selective loss/decrease of regulatory T cells (Tregs) in thymomas</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A reduction in thymic-derived regulatory T cells in patients with thymomas, which would impair peripheral immunoregulation and permit autoreactive responses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Selective loss of regulatory T cells in thymomas.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis and other thymoma-associated autoimmunity</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Loss or reduction of Tregs from the thymic environment decreases central/peripheral tolerance mechanisms, enabling expansion of autoreactive effector T cells.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Studies (Strobel et al.) documenting decreased regulatory T-cell numbers in thymoma tissue and/or circulation in affected patients.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Decreased Tregs in thymomas offer a mechanistic explanation for failure of immune regulation and development of paraneoplastic autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Evidence primarily descriptive; functional impairment of regulation demonstrated incompletely in humans.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e263.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Autoantibodies</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Autoantibodies (AChR, titin, ryanodine receptor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Autoantibodies against neuromuscular and muscle antigens (most commonly acetylcholine receptor, and coexisting antibodies such as titin and ryanodine receptor) that mediate or signal severe myasthenia gravis and associate with thymoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis (AChR antibodies), with titin and RyR antibodies as markers/coexisting antibodies linked to thymoma</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Autoantibodies produced by B cells (helped by autoreactive T cells) target neuromuscular junction components (AChR) causing clinical MG; presence of titin and RyR antibodies is associated with thymoma and more severe disease.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Clinical serology studies demonstrating AChR antibodies in many MG patients; studies showing titin and RyR antibodies co-occur with thymoma and predict more severe disease.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Some thymoma-associated MG patients are seronegative for AChR, indicating not all cases are explained by known autoantibodies.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Autoantibodies are central to MG pathogenesis and their patterns (AChR, titin, RyR) help link thymoma to autoimmune phenotype and severity.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Not all patients are seropositive; serology alone does not capture all mechanisms of autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e263.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Seronegative MG</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Thymoma-associated myasthenia gravis without detectable AChR antibodies</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Clinical cases where patients with thymoma develop MG but test negative for acetylcholine receptor antibodies, implying alternative immune mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis (seronegative subtype)</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td>Reported but uncommon; specific counts in ITMIG cohort not provided</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Alternative immune mechanisms such as antibodies to other antigens, T-cell–mediated effects, or undetected low-titer antibodies may underlie seronegative MG associated with thymoma.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Case reports and small series documenting MG phenotype in thymoma patients lacking detectable AChR antibodies (refs cited).</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Presence of seronegative MG demonstrates that thymoma-associated autoimmunity can occur independent of classical AChR seropositivity and supports involvement of additional immune pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Data largely case-based; mechanisms speculative without broad mechanistic studies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e263.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e263.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Clinical associations (ITMIG)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Clinical and pathological associations between PN/AI syndromes and thymomas (ITMIG retrospective findings)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Large registry-derived clinical associations showing PN/AI syndromes (mostly MG) are linked to younger age, female sex, WHO B1/B2 histotypes, earlier stage, higher rates of total thymectomy and R0 resection, and better unadjusted recurrence and survival but not independently prognostic.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis (predominant), pure red cell aplasia, hypogammaglobulinemia, and other autoimmune syndromes (rare)</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td>In the ITMIG cohort of 6297 TET patients, PN/AI syndromes occurred in 34.0% (2143 patients); MG in 32.8% (2068 patients); pure red cell aplasia in 0.7% (47), hypogammaglobulinemia in 0.2% (13).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Clinical associations are consistent with mechanisms of impaired thymic selection and altered thymic microenvironment (AIRE loss, decreased MHCII, abnormal thymopoiesis, reduced Tregs) described in mechanistic studies.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Large multi-continent retrospective dataset showing demographic, histologic, stage, surgical and outcome correlations; supports epidemiologic link between thymoma and PN/AI but not causation.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>In multivariate models, PN/AI syndrome was not an independent predictor of recurrence-free or overall survival, suggesting the association with favorable outcomes is confounded by stage, histology, resection status, and other factors.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td>PN/AI(+) patients: median age 50 (range 5–89), 52.8% female, more commonly European; PN/AI(-) median age 55, predominantly male and Asian.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>PN/AI(+) patients more commonly received total thymectomy (90% vs. 77%) and had higher rates of R0 resection (87.2% vs. 81.5%); curative-intent radiation associated with improved RFS/OS overall (not specific to PN/AI).</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>PN/AI syndromes are common in thymomas and associate with distinct clinical/pathologic features; although unadjusted analyses show better outcomes in PN/AI(+) patients, PN/AI status itself is not an independent prognostic factor after multivariate adjustment.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Retrospective registry with missing data, no central pathology review, variable follow-up protocols, short median follow-up (~3.7 years), >90% missing cause-of-death data, potential lead-time and selection biases.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. <em>(Rating: 2)</em></li>
                <li>Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. <em>(Rating: 2)</em></li>
                <li>Selective loss of regulatory T cells in thymomas. <em>(Rating: 2)</em></li>
                <li>Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). <em>(Rating: 2)</em></li>
                <li>Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. <em>(Rating: 2)</em></li>
                <li>Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. <em>(Rating: 2)</em></li>
                <li>Antititin antibody in early- and late-onset myasthenia gravis. <em>(Rating: 1)</em></li>
                <li>Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. <em>(Rating: 1)</em></li>
                <li>Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies. <em>(Rating: 1)</em></li>
                <li>Randomized Trial of Thymectomy in Myasthenia Gravis. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>